BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 19, 2009
 |  BC Week In Review  |  Company News  |  Deals

EffRx Inc., Nycomed Group A/S deal

EffRx granted Nycomed exclusive rights to develop and commercialize EX101 to treat musculoskeletal diseases, except hypercalcemia of malignancy, in Canada, Europe, Latin America, the Middle East, North Africa and Russia. The effervescent formulation of alendronate is in pivotal...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >